When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence.
anti-p105 pemphigoid
anti-p200 pemphigoid
autoimmune bullous disease
bullous pemphigoid
direct immunofluorescence
indirect immunofluorescence
laminin gamma-1
salt-split skin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
accepted:
12
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Bullous pemphigoid (BP) is the most common autoimmune bullous disease, but rarer forms of pemphigoid may appear identical to BP on routine histopathology and direct immunofluorescence (DIF). Here, we present the case of a 60-year-old man, who was initially thought to have BP, with supportive findings on routine histopathology and DIF. However, prominent oral involvement and cutaneous lesions refractory to conventional treatment suggested an alternate diagnosis. Further workup was performed, including indirect immunofluorescence (IIF) on salt-split skin, which showed binding of antibodies to the dermal floor rather than to the blister roof, and enzyme-linked immunosorbent assay for pemphigus and pemphigoid antibodies. With these additional tests, we concluded that the patient does not have BP but rather anti-p200 pemphigoid, anti-p105 pemphigoid, or a yet undiscovered form of pemphigoid. We reached a presumptive diagnosis of anti-p200 pemphigoid, as it is the most common pemphigoid with serum antibodies to the dermal floor of human salt-split skin by IIF. This case demonstrates that suspicion for other autoimmune bullous diseases in cases of treatment-refractory and clinically aberrant BP is essential. A limited workup may lead to a missed diagnosis and ultimately less efficient disease management.
Identifiants
pubmed: 35308677
doi: 10.7759/cureus.22201
pmc: PMC8925621
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e22201Informations de copyright
Copyright © 2022, Hopkins et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Immunol. 2019 Oct 22;10:2466
pubmed: 31695695
Am J Dermatopathol. 2007 Apr;29(2):119-24
pubmed: 17414431
JAMA Dermatol. 2016 Aug 1;152(8):897-904
pubmed: 27167149
Actas Dermosifiliogr. 2017 Jan - Feb;108(1):e1-e5
pubmed: 27095685
Front Med (Lausanne). 2018 Nov 02;5:296
pubmed: 30450358
Arch Dermatol. 1994 Mar;130(3):343-7
pubmed: 8129413
Br J Dermatol. 2004 Jul;151(1):112-8
pubmed: 15270879
An Bras Dermatol. 2019 Mar-Apr;94(2):133-146
pubmed: 31090818
J Am Acad Dermatol. 2019 Nov;81(5):1195-1197
pubmed: 30953703